Financial Data and Key Metrics Changes - Fiscal year 2025 revenue totaled $5.43 billion, reflecting a 2.4% increase year-over-year, with an organic growth rate of 3.9% [26][29] - Adjusted EBITDA margin for the full year was 12.9%, up from 11.6% in the prior year, and adjusted earnings per share were $7.36, a 20% increase from $6.11 [26][29] - Free cash flow for fiscal year 2025 was $366 million, with strong cash flows of $642 million in the fourth quarter alone [26][33] Business Line Data and Key Metrics Changes - The U.S. federal services segment achieved 12.1% organic growth, while the outside-the-U.S. segment delivered 4.1% organic growth [5][29] - Revenue for the U.S. services segment decreased to $1.76 billion from $1.91 billion, with an operating income margin of 9.7%, down from 12.9% in the prior year [31][32] - The outside-the-U.S. segment's revenue decreased to $600 million due to divestitures, but it experienced positive organic growth of 4.1% [32] Market Data and Key Metrics Changes - The total pipeline at September 30 was $51.3 billion, up from $44.7 billion in the previous quarter, with 64% representing new work [24] - Approximately 66% of the total pipeline is attributable to the U.S. federal services segment, with significant opportunities tied to the One Big Beautiful Bill Act still in development [24] Company Strategy and Development Direction - The company is focused on three strategic priorities for fiscal year 2026: expanding in U.S. federal markets, policy-driven initiatives, and deploying AI and tech-enabled automation [7][8] - Investments in AI capabilities are a key priority, aimed at transforming service delivery and enhancing operational efficiency [20][21] - The company aims to maintain a disciplined approach to capital allocation, prioritizing organic investments, dividends, and strategic acquisitions [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth opportunities, citing strong customer relationships and strategic investments as key drivers [7][9] - The company anticipates that fiscal 2026 will be defined by shaping efforts, with actual work and revenue expected to materialize in fiscal year 2027 [43] - Management noted that the impact of the recent government shutdown is expected to be minimal, as most programs are deemed essential services [55][57] Other Important Information - The company repurchased approximately $457 million worth of shares during fiscal year 2025, with a remaining authorization of $250 million [34][35] - The adjusted EPS guidance for fiscal year 2026 is projected to be between $7.95 and $8.25, with a midpoint of $8.10 [37][41] Q&A Session Summary Question: Can you provide more color on what's driving the EBITDA margin expansion for 2026? - Management indicated that the margin guidance reflects continued deployment of technology and automation, along with cost management efforts [47][50] Question: How are you thinking about the effects of the government shutdown on your results? - Management does not anticipate negative impacts on contract delivery, as most programs were funded prior to the shutdown [55][56] Question: What are your priorities for allocating capital in the short term? - The company remains focused on growth in the U.S. federal market, particularly in defense and national security, while also considering M&A opportunities [60][63] Question: What phase of the opportunity related to the One Big Beautiful Bill are you currently in? - Management noted that states are actively planning for compliance with new requirements, with significant urgency around SNAP payment error rates [66][68]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $26.4 million, representing a 14% year-over-year increase [5][12] - Non-GAAP operating income was $3.7 million, compared to $1.1 million in Q3 2024 [14][15] - Non-GAAP net income was $4.6 million, or $0.10 per diluted share, compared to $1.3 million, or $0.03 per diluted share, in the same quarter last year [15] - Cash and investments totaled $81 million as of September 30, 2025, up from $59 million at the end of 2024, with no debt [15][16] Business Line Data and Key Metrics Changes - Revenue from Cybersecurity as a Service (CCAs) was $7.3 million, up 60% year-over-year, comprising 28% of total revenue [12][5] - CCAs Annual Recurring Revenue (ARR) as of September 2025 was $27.6 million [12] - The Smart product line also contributed to growth, with a strong performance and a robust pipeline [9][10] Market Data and Key Metrics Changes - Increased sales in the Americas, particularly from a large Smart order and growing contributions from the U.S. market [12] - Recurring revenue as a percentage of total revenue increased to 63% in Q3 2025 from 58% in Q3 2024 [13] Company Strategy and Development Direction - The company is executing a cybersecurity-first strategy and focusing on a renewed go-to-market approach [7][10] - The launch of OPNET Secure aims to enhance cybersecurity protection for end customers, expanding the service beyond the operator's infrastructure [8] - The company is optimistic about long-term growth, with expectations for CCAs ARR to surpass 60% year-over-year growth by year-end 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and growth strategy, highlighting the positive momentum in CCAs and network intelligence solutions [10][11] - The competitive landscape is viewed as more favorable, with unique technology providing a competitive edge [29] - Management raised full-year 2025 revenue guidance to between $100 million and $103 million [11] Other Important Information - The company completed a $46 million follow-on share offering, with $40 million received in Q2 and $6 million in Q3 [15] - The company reported positive operating cash flow of $4 million for the third consecutive quarter [15] Q&A Session Summary Question: Increased traction with major telecom customer - Management noted positive trends in both tax rates and new services launched, contributing to significant growth in CCAs revenue and ARR [18] Question: Details on the first customer for OPNET Secure - Management indicated that the first customer values 24/7 protection and is looking to enhance their service with OPNET [19][21] Question: Continued strength in the Smart pipeline - Management confirmed a strong pipeline with opportunities from both new and existing customers, particularly for the Terra 3 product [23] Question: Drivers of CCAs growth - Growth is primarily from new contracts and the onboarding of additional customers, with a focus on strategic accounts [27] Question: Competitive landscape for network intelligence offerings - Management described the competitive landscape as easier, with unique technology providing a competitive edge [28] Question: Drivers of growth in larger CCAs contracts - Management identified new customer additions, upselling, and cross-selling as key growth drivers [32] Question: Progress with Verizon Live's penetration - Management refrained from discussing specific customers but expressed overall satisfaction with progress [39] Question: Role of Terra 3 in customer conversations - Management highlighted a good mix of new opportunities and discussions with existing customers, focusing on customer success [41]

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported revenue of $5.43 billion, reflecting an organic growth rate of 3.9% compared to the previous year [25][27] - The adjusted EBITDA margin for the full year was 12.9%, an increase from 11.6% in the prior year, while adjusted earnings per share rose to $7.36 from $6.11, representing a 20% increase [27][28] - Free cash flow for fiscal year 2025 totaled $366 million, with strong cash flows of $642 million in the fourth quarter alone [25][31] Business Line Data and Key Metrics Changes - The U.S. federal services segment achieved 12.1% organic growth, driven by high demand in clinical and disaster support programs [5][27] - The U.S. services segment revenue decreased to $1.76 billion, with an operating income margin of 9.7%, down from 12.9% in the prior year due to the completion of pandemic-related engagements [29][30] - The outside-the-U.S. segment reported revenue of $600 million, with a 4.1% organic growth rate, and an operating income margin improved to 3.7% from 1.2% in the prior year [30] Market Data and Key Metrics Changes - The total pipeline of sales opportunities as of September 30 was $51.3 billion, up from $44.7 billion in the previous quarter, with 66% of this attributed to the U.S. federal services segment [24][22] - Approximately 64% of the total pipeline represents new work, indicating a strong future growth potential [24] Company Strategy and Development Direction - The company is focusing on three strategic priorities for fiscal year 2026: expanding in U.S. federal markets, policy-driven initiatives related to the One Big Beautiful Bill Act, and deploying AI and tech-enabled automation [8][10] - Investments in AI capabilities are seen as crucial for transforming service delivery and enhancing operational efficiency [21][22] - The company aims to maintain a disciplined approach to capital allocation, prioritizing organic investments, dividends, and strategic acquisitions to accelerate growth [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth, citing strong customer relationships and a robust pipeline of opportunities, particularly in the U.S. federal services segment [7][42] - The company anticipates that fiscal year 2026 will be characterized by shaping efforts, with actual revenue growth expected to materialize in fiscal year 2027 [42][43] - Management noted that the impact of the recent government shutdown is expected to be minimal, as most programs are deemed essential services [48][49] Other Important Information - The company repurchased approximately $457 million worth of shares during fiscal year 2025, with a remaining authorization of $250 million for future repurchases [32][33] - The adjusted EPS guidance for fiscal year 2026 is projected to be between $7.95 and $8.25, reflecting ongoing margin expansion and growth [36][40] Q&A Session Summary Question: Can you provide more color on what's driving the EBITDA margin expansion for 2026? - Management indicated that the margin guidance reflects continued deployment of technology and automation, along with cost management initiatives [44][45] Question: How do you anticipate the government shutdown affecting results? - Management stated that they do not expect negative impacts on contract delivery, as most programs were funded prior to the shutdown [48][49] Question: What are the priorities for allocating capital in the short term? - The company emphasized a focus on growth in the U.S. federal market, particularly in defense and national security, while also considering M&A opportunities [51][52]

Financial Data and Key Metrics Changes - Total revenues reached EUR 127 million for the nine months ended September 30, 2025, representing a growth of almost 9% compared to EUR 112.5 million in the same period of 2024 [4][16] - Product sales increased to EUR 119.4 million, up 6.2% from EUR 112 million in the first nine months of 2024 [14] - Operating loss reported at EUR 53.9 million compared to an operating profit of EUR 34.2 million in the prior year, primarily due to the sale of a priority review voucher in the previous year [18] Business Line Data and Key Metrics Changes - IXIARO sales reached EUR 74.3 million, increasing 12.5% year-over-year, driven by sales to the U.S. Department of Defense and increased sales in some European countries [14] - Ducoral sales decreased from EUR 22.3 million to EUR 21.5 million, impacted by foreign currency fluctuations and lower sales during the transition to a new distributor in Germany [14][15] - Exchange sales significantly increased to EUR 7.6 million from EUR 1.8 million, including the supply of doses to combat a chikungunya outbreak [15] Market Data and Key Metrics Changes - The company is focusing on expanding into low- and middle-income countries (LMICs) and new territories for IXIARO, leveraging its differentiated product profile [20][21] - The Lyme disease vaccine, VLA15, is expected to be a major growth driver, with regulatory submissions anticipated in 2026 and a potential launch in autumn 2027 [20][31] Company Strategy and Development Direction - The company aims to achieve sustainable profitability post-approval and commercialization of the Lyme disease vaccine, which is seen as a significant growth catalyst [20][21] - Valneva is actively identifying new opportunities for its R&D pipeline, aiming to build a coherent strategy for future vaccine candidates [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming Lyme disease vaccine data, which is expected to be a pivotal moment for the company [20][37] - The company is focused on reducing cash burn and ensuring sufficient runway to reach key inflection points, with cash at September 30 reported at EUR 143.5 million [18][19] Other Important Information - The company successfully completed debt refinancing, enhancing financial flexibility [5] - Research and development expenses increased to EUR 59.7 million, partly due to costs related to the Shigella vaccine candidate [17] Q&A Session Summary Question: Timeline for FDA response regarding exchange - Management indicated there is no predefined process for the FDA response and hopes for a collaborative interaction [24][25] Question: Impact of currency and distributor shift on Ducoral sales - Management noted that the transition to a new distributor in Germany caused a technical delay in purchases, but growth for Ducoral is expected to continue [25][26] Question: Timing for Lyme phase 3 readout - Management stated that Pfizer controls the process and is taking steps to ensure an early readout, with no major delays anticipated [27][28] Question: Remedies proposed to FDA for exchange BLA suspension - The response to the FDA focused on medical evidence and positive risk-benefit ratios, with ongoing pharmacovigilance reviews [29] Question: Launch timeline for VLA15 - Management confirmed that timelines communicated by Pfizer support a launch in the autumn of 2027, contingent on regulatory submissions next year [30][31] Question: Funding considerations for Zika vaccine candidate - Management highlighted uncertainty around funding and regulatory pathways, indicating that substantial funding would be necessary to proceed with development [33][36]

Financial Data and Key Metrics Changes - The stockholders approved the proposal to grant discretionary authority to the Board of Directors for a reverse stock split within a range of 1-for-2 to a maximum of 1-for-10, indicating a strategic move to potentially enhance share value [12][13][14] - The company successfully ratified the selection of M&K CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2025, ensuring compliance and transparency in financial reporting [15] Business Line Data and Key Metrics Changes - The amendment to the 2022 equity incentive plan to increase the number of shares authorized for issuance to 5 million was approved, which may impact employee compensation and retention strategies [14] Market Data and Key Metrics Changes - The approval of the issuance of shares to Streeterville Capital, LLC, in prepaid financing transactions that may collectively equal or exceed 20% of the issued and outstanding shares indicates a significant capital raise strategy [14] Company Strategy and Development Direction - The company is pursuing a reincorporation from Delaware to Nevada, which may provide more favorable business regulations and tax benefits [13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting, focusing instead on the proposals and voting results Other Important Information - The meeting concluded with the election of seven directors, ensuring continuity in governance and strategic direction [12][13] Summary of Q&A Session - There were no recorded questions or answers during the meeting, as the focus was primarily on the proposals and voting outcomes

Financial Data and Key Metrics Changes - The company reported Q3 EPS of $0.53 and net sales of $297.2 million, both exceeding consensus expectations [3] - Gross profit margin expanded by 160 basis points to 37.6%, driven by disciplined pricing and a shift towards higher-income customers [4][17] - Net income for Q3 was $14.6 million, down from $19.2 million year-over-year, primarily due to re-banner investments impacting EPS by $0.22 [18] Business Line Data and Key Metrics Changes - Shoe Station net sales grew by 5.3%, while Shoe Carnival net sales declined by 5.2%, reflecting a significant performance gap of 10.5 percentage points [5][15] - Athletics represented 51% of total sales in Q3, with low single-digit growth overall, while non-athletic categories saw a mid-single-digit comp decline [4][16] - Shoe Station's product margins expanded by 260 basis points, contrasting with Shoe Carnival's decline due to economic pressures on lower-income households [5][18] Market Data and Key Metrics Changes - The company is strategically shifting away from lower-income households, focusing on customers with median incomes of $60,000-$100,000 [5][9] - The competitive response in the lower-income segment is driving margins down across the industry, while Shoe Station is positioned to capture premium brand demand [5][9] Company Strategy and Development Direction - The company plans to consolidate to one brand, Shoe Station, to improve operational efficiency and capitalize on the stronger performance of this banner [8][9] - By the end of fiscal 2027, the company expects to achieve $20 million in annual cost savings and $100 million in working capital freed from inventory reduction [9][27] - The transition to Shoe Station is expected to restore comparable sales growth and expand EPS significantly by fiscal 2028 [12][27] Management's Comments on Operating Environment and Future Outlook - Management highlighted that fiscal 2026 will be an investment year, with expectations of continued pressure on sales in the first half, followed by a potential turnaround in the second half as Shoe Station becomes the dominant brand [22][23] - The company remains debt-free with over $100 million in cash, allowing it to fund its transformation without external financing [10][13] - Management expressed confidence in the long-term value creation potential of the one-banner strategy, emphasizing the shift in consumer preferences towards premium brands [29] Other Important Information - The company completed 101 store re-banners during fiscal 2025, with plans to reach 51% of its stores operating as Shoe Station by back-to-school 2026 [7][28] - The Rogan's acquisition is fully integrated into Shoe Station, and results will be reported under this banner starting in Q4 [20] Q&A Session Summary Question: What is the expected drag on earnings from re-bannering next year? - Management indicated that re-banner expenses for the next year are expected to be between $25 million and $30 million, with costs being front-loaded due to the conversion of approximately 70 stores [30][31] Question: How will the company manage inventory reductions? - The company plans to liquidate non-GoForward products aggressively and expects some margin pressure during this process [52][53] Question: What is the outlook for the boot business? - Management noted that while the boot season started slowly, there were double-digit increases in sales as inventory improved in October [35] Question: Will the company be able to elevate its product assortment at Shoe Station? - Management confirmed that there are ongoing discussions with premium brands to enhance the product assortment at Shoe Station [37] Question: What is the timeline for achieving the 80% re-bannering goal? - Management stated that the focus is on reaching the critical 51% threshold by summer 2026, with plans to exceed 90% by the end of fiscal 2028 [54]

Financial Data and Key Metrics Changes - For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from approximately $4 million in the same period last year, primarily due to lower revenue from AgPlenus activity [9][31] - Total operating loss for the nine months of 2025 was approximately $8.8 million, a significant decrease from approximately $15.3 million in the same period of the previous year, mainly due to reduced operating expenses [10][35] - The net loss for the nine months of 2025 was approximately $2.5 million compared to approximately $18 million in the same period last year, reflecting a $15.5 million decrease primarily due to decreased operating expenses and income from discontinued operations [37][38] Business Line Data and Key Metrics Changes - The financial results of Lavie Bio, Evogene's subsidiary, are presented as a single line item in the consolidated P&L statement for 2025, reflecting the sale of the majority of its activities to ICL [8][29] - Research and development expenses for the nine months of 2025 were approximately $6.2 million, a decrease of approximately $3.6 million compared to $9.8 million in the nine months of 2024, primarily due to reduced R&D expenses in Biomica and the cessation of Canonic's operations [31][32] - Sales and marketing expenses for the nine months of 2025 were approximately $1.2 million, a decrease of approximately $400,000 compared to approximately $1.6 million in the same period last year, mainly due to personnel cost reductions [10][32] Market Data and Key Metrics Changes - The global agricultural market was valued at $79 billion in 2024, with significant opportunities for new product development in herbicides, insecticides, and fungicides [21] - The global pharmaceutical market for small molecule-based drugs is valued at approximately $780 billion, representing nearly 60% of the market [23] Company Strategy and Development Direction - The company is transitioning to focus on computational chemistry and generative design of small molecules for the pharmaceutical and agriculture industries [6][7] - The strategy includes leveraging the proprietary generative AI tech engine, Campus AI, to design novel small molecules that meet multiple parameters for commercial success [12][18] - The company aims to strengthen collaborations with leading global companies in both agriculture and pharmaceuticals to drive innovation and product development [28][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increased interest in AI-driven drug discovery following recent partnerships in the industry, indicating a positive outlook for Evogene's technology [39][40] - The company expects to announce additional collaborations in the pharma division and expand existing partnerships in agriculture, which are anticipated to generate cash inflows [47][48] Other Important Information - The company completed a cost reduction plan, which is reflected in the reduced operating expenses for the third quarter of 2025 [8][29] - The cash balance as of September 30, 2025, was approximately $16 million, reflecting proceeds from the sale of Lavie Bio's assets [10][30] Q&A Session Summary Question: Has the levels of interest in AI champs increased post the recent NVIDIA Eli Lilly AI drug discovery partnerships? - Management noted that the announcement increased interest in AI-related activities in the pharma industry, and they have seen growing interest in their technology [39][40] Question: How close are you to unlocking partners with AI champs? - Management indicated that interest has increased significantly, and they expect to announce new collaborations with biotech companies early next year [43][44] Question: What is the IR strategy going forward? - Management confirmed that they will focus on presenting the new company strategy and will initiate roadshows and participate in conferences to increase visibility [45][46] Question: Could you highlight upcoming catalysts over the coming 6-12 months? - Management expects to announce new collaborations in both the pharma and ag divisions, as well as additional partnerships with major tech companies [47] Question: What type of revenue level can we expect for customer seeds in Q4 and for 2026? - Management refrained from disclosing specific revenue levels but mentioned ongoing discussions with strategic companies that could significantly impact future revenue [48] Question: How excited are you about AI champs compared to all your other times at Evogene? - Management expressed optimism about the focus on the pharma industry, highlighting the unique expertise of their team and the potential for significant financial rewards [49][50]

Financial Data and Key Metrics Changes - Time charter revenues for Q3 2025 were $51.9 million, down from $57.5 million in the same quarter last year, reflecting the sale of two vessels earlier this year [10] - Adjusted EBITDA decreased to $20.3 million from $23.7 million year-over-year, consistent with a smaller fleet [10] - Net income nearly doubled to $7.2 million from $3.7 million in Q3 2024, driven by lower expenses and a $10.6 million gain from the valuation of the investment in Genco [10] - Cash decreased to $133.9 million as of September 30, 2025, from $207.2 million at the end of 2024, due to strategic investments [11] - Long-term debt increased slightly to $651.1 million as of September 30, 2025, from $637.5 million at year-end 2024 [12] Business Line Data and Key Metrics Changes - Fleet utilization reached 99.5% for Q3 2025, indicating effective vessel management [4] - Time charter equivalent averaged $15,178 per day, a 1% decrease compared to $15,333 per day in Q3 2024 [12] - Daily operating expenses rose 1% to $6,014 compared to $5,964 last year, mainly due to higher crew costs [13] Market Data and Key Metrics Changes - The dry bulk market showed solid performance in Q3, with record Chinese imports reaching nearly 580 million metric tons [3] - The 12-month time charter rate for a typical Capesize stood at around $24,000 a day, with rates for Campermax and Ultramax at $15,600 and $15,900 respectively, all up from earlier in the year [18] - The Baltic Capesize Index was at 3,636, and the Baltic Panamax Index at 1,895 as of November 19 [18] Company Strategy and Development Direction - The company is focused on fleet modernization and sustainability, with plans to deliver two methanol dual-fuel new-building Campermax vessels by early 2028 [4] - A disciplined chartering strategy has secured approximately $149 million in contracted revenues, ensuring earnings visibility and resilience against market downturns [8] - The company is committed to promoting eco-friendly technologies and transparency in emissions data as part of its ESG initiatives [32] Management Comments on Operating Environment and Future Outlook - Management noted that the bulk carrier market has weathered geopolitical and trade developments well, with positive sentiment and new building orders appearing [18] - The outlook for 2026 appears positive, with projected revenues supporting a return to cash flow profitability despite potential challenges in 2025 [15] - The company is observing developments in Genco Shipping and Trading Limited, considering its strategic stake [33] Other Important Information - The company declared a quarterly cash dividend of $0.01 per common share for Q3 2025, totaling approximately $1.16 million [6] - The average age of the fleet is approximately 12 years, with ongoing efforts to modernize [14] Q&A Session Summary Question: How should we think about your significant stake in Genco now? - Management stated that the position in Genco has strategic value, and they are currently observing developments without direct contact with Genco's management [33] Question: Can you comment on the recent development in Ocean Chow? - Management indicated that Diana Shipping's interest in Ocean Chow is minimal and not material at this stage [34]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $26.4 million, representing a 14% year-over-year increase [5][11] - Non-GAAP operating income was $3.7 million, compared to $1.1 million in Q3 2024 [12] - Non-GAAP net income was $4.6 million, or $0.10 per diluted share, compared to $1.3 million, or $0.03 per diluted share, in the same quarter last year [13][14] - Cash and investments totaled $81 million as of September 30, 2025, up from $59 million at the end of 2024, with no debt [15] Business Line Data and Key Metrics Changes - Cybersecurity as a Service (CCAS) revenue was $7.3 million in Q3 2025, up 60% year-over-year, comprising 28% of total revenue [11][12] - CCAS Annual Recurring Revenue (ARR) as of September 2025 was $27.6 million [11] - The Smart product for network intelligence also contributed to growth, with a strong pipeline and backlog [8][9] Market Data and Key Metrics Changes - Increased sales in the Americas, particularly from a large Smart order and growing contributions from the U.S. market [11] - Recurring revenue as a percentage of total revenue increased to 63% in Q3 2025, up from 58% in Q3 2024 [12] Company Strategy and Development Direction - The company is executing a cybersecurity-first strategy and focusing on a renewed go-to-market approach [6][9] - The introduction of OPNET Secure aims to enhance cybersecurity protection for end customers, expanding the service beyond the operator's infrastructure [7][19] - The company is optimistic about long-term growth, with expectations for CCAS ARR to surpass 60% year-over-year growth by year-end 2025 [10][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position and growth strategy, highlighting the positive momentum in CCAS and network intelligence solutions [6][9] - The competitive landscape is viewed as more favorable, with unique technology providing a competitive edge [25] - Management anticipates continued growth in both CCAS and Smart product lines, supported by a robust pipeline and backlog [9][11] Other Important Information - The company completed a $46 million follow-on share offering, enhancing its financial resources for growth initiatives [14] - The company reported positive operating cash flow for the third consecutive quarter, totaling $4 million in Q3 2025 [14] Q&A Session Summary Question: Increased traction with major telecom customers - Management noted positive trends in both tax rates and new services launched, contributing to significant growth in CCAS revenue and ARR [17] Question: Details on the first customer for OPNET Secure - The first customer aims for 24/7 protection for their customers, combining network security with OPNET services [19][20] Question: Drivers of CCAS growth - Growth is primarily from new customer contracts and the onboarding of additional customers from existing contracts [23] Question: Competitive landscape for network intelligence offerings - The competitive environment is currently more favorable, with unique technology providing a competitive edge [25] Question: Drivers of growth in larger CCAS contracts - Growth is driven by new customer additions and upselling additional services to existing customers [28] Question: Terra 3's role in customer conversations - The company is focusing on customer success and maintaining a healthy mix of new and existing customer opportunities [35]

Financial Data and Key Metrics Changes - The company reported a 24% year-over-year revenue growth, reaching $148 million in Q3 2025, exceeding guidance of 21% to 23% [16][19] - Adjusted diluted earnings per share increased to $0.40, surpassing guidance of $0.33 to $0.36 [18] - Gross margins expanded to 71.6%, up 170 basis points from the previous year, exceeding guidance of 68% [17] - Adjusted EBITDA for the quarter was $29 million, above the guidance of $26 million to $28 million [18] Business Line Data and Key Metrics Changes - Il Makiage experienced double-digit online revenue growth, with a target of $1 billion revenue by 2028 [11] - SpoiledChild is expected to generate $225 million in revenue for 2025, indicating strong performance [12] - International revenue increased approximately 40% year-over-year in the first nine months of 2025, with successful scaling in existing markets [11] Market Data and Key Metrics Changes - The company noted that 83% of revenue still comes from the U.S., with international markets contributing 17% [23] - New geographic expansions include Italy, Spain, Netherlands, Ireland, Sweden, and Denmark, with testing in Japan, Mexico, and Korea [24] Company Strategy and Development Direction - The launch of Methodic, a new brand focused on dermatology, aims to transform medical care with high-efficacy treatments [5][6] - The company plans to expand Methodic into new medical domains beyond dermatology in the future [7] - Continued investment in technology and innovation, particularly in AI and proprietary datasets, is a key focus for driving direct-to-consumer growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging industry backdrop, citing strong repeat customer rates as a buffer against acquisition cost increases [40] - The outlook for 2025 has been raised, with expected net revenue between $806 million and $809 million, representing 24% to 25% year-over-year growth [19] Other Important Information - The company ended the quarter with $793 million in cash and cash equivalents, plus an additional $200 million available on undrawn credit facilities [19] - Methodic's launch includes a significant media campaign, marking the largest TikTok activation in the company's history [10] Q&A Session Summary Question: Can you unpack the 40% year-to-date growth in international markets? - Management noted that 83% of revenue still comes from the U.S., with international growth being strategically important and focused on existing markets [23][24] Question: Thoughts on Methodic's ability to bring in new customers? - Management indicated that Methodic will attract both new and existing customers, with a mixed approach to user acquisition [25][27] Question: How to think about Methodic's brand for 2026? - Expectations are for Methodic to scale faster than SpoiledChild, with a focus on user acquisition and long-term growth [32][34] Question: Views on the health of the U.S. consumer? - Management acknowledged external softness but highlighted strong internal performance and repeat customer growth as mitigating factors [40] Question: Is the growth algorithm for 2026 any different? - No changes to the growth algorithm of 20% revenue growth and 20% adjusted EBITDA margin were indicated [42] Question: How replicable is the data model for international efforts? - Management confirmed a measured approach for Methodic, starting only in the U.S. before considering international expansion [64] Question: Are the molecules for Methodic prescription or non-prescription? - The initial products will be a combination of OTC and cosmetic, with a focus on non-prescription offerings [67][93] Question: What is the total addressable market (TAM) for Methodic? - The TAM is viewed in terms of the number of people suffering from chronic skin conditions, with a focus on improving access and outcomes [84]